New User:
-or-
Username:
Password:
Forgot your password?
News Breaks
November 9, 2009
07:12 EDTAMRI
theflyonthewall.com: Albany Molecular sees FY09 EPS (1c)-(5c) vs. consensus of 13c
AMRI CFO Mark T. Frost said: "EPS includes the impact of the $1.9M, or 4c per basic and diluted share, of non-cash inventory write-downs primarily related to a legacy generic API recorded in the Q2. The revised full year guidance includes a lower tax benefit due to the mix of domestic and international pre-tax income/loss as well as a catch-up for 2008 income taxes. Forecasted operating results for the full year 2009 have not significantly changed from our previous guidance". :theflyonthewall.com



News For AMRI From The Last 14 Days
Check below for free stories on AMRI the last two weeks.
There are 6 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing.
February 7, 2012
08:11 EDTAMRI
theflyonthewall.com: Albany Molecular 2012 R&D expense will decrease approximately $1M

Subscribe for More Information :theflyonthewall.com
08:10 EDTAMRI
theflyonthewall.com: Albany Molecular sees 2012 contract gross margin 45-8%

Subscribe for More Information :theflyonthewall.com
08:10 EDTAMRI
theflyonthewall.com: Albany Molecular sees Q1 Allegra royalties $10M-$12M

Subscribe for More Information :theflyonthewall.com
08:08 EDTAMRI
theflyonthewall.com: Albany Molecular sees Q1 contract revenue $37M-$40M

Subscribe for More Information :theflyonthewall.com
08:07 EDTAMRI
theflyonthewall.com: Albany Molecular Q4 total contract revenue $39.4M
:theflyonthewall.com
08:07 EDTAMRI
theflyonthewall.com: Albany Molecular reports Q4 adjusted EPS (19c) vs. consensus (12c)

Subscribe for More Information :theflyonthewall.com